ASCO 2022
ASCO 2022 Prostate Cancer
- ASCO 2022: Association of RB1 Mutational Status with Overall Genomic Landscape in Neuroendocrine Prostate Cancer (NEPC)
- ASCO 2022: Circulating Tumour Cells (CTCs) and PSMA PET Correlates in the Phase I PRINCE Trial of 177Lu-PSMA-617 plus Pembrolizumab for Metastatic Castration Resistant Prostate Cancer (mCRPC)
- ASCO 2022: T-cell Redirection in Advanced Prostate Cancer to Prevent Cancer Progression and Death - Discussion
- ASCO 2022: Future Targets for Cellular Therapy in Prostate Cancer
- ASCO 2022: CAR T for Prostate Cancer: Current Strategies to Improve Efficacy
ASCO 2022 Bladder Cancer
- ASCO 2022: Preliminary Results of a Phase Ib/II Combination Study of RC48-ADC, a Novel Humanized Anti-HER2 Antibody-Drug Conjugate With Toripalimab, a Humanized IgG4 mAb Against PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
- ASCO 2022: HER-2 Is New Again in Bladder Cancer - Discussion
- ASCO 2022: Improving Outcomes Across the Stages in Bladder Cancer - Discussion
- ASCO 2022: Long-Term Outcomes in EV-301: 24-Month Findings From the Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma
- ASCO 2022: Perioperative Chemoimmunotherapy With Durvalumab for Operable Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single Arm Phase II Trial SAKK 06/17
ASCO 2022 Kidney Cancer
- ASCO 2022: Moving Beyond TKI and Immuno-oncology in Renal Cell Carcinoma - Discussion
- ASCO 2022: Sequencing Challenges in Renal Cell Carcinoma: What to Do Next? - Discussion
- ASCO 2022: Pembrolizumab + Axitinib Versus Sunitinib As First-Line Therapy for Advanced Clear Cell RCC: Analysis of Progression After First Subsequent Therapy in KEYNOTE-426
- ASCO 2022: Racial Differences in Treatment Patterns and Outcomes of First-Line Therapies for Advanced RCC in the Real-World Setting
- ASCO 2022: Healthcare Resource Utilization and Costs for Patients With mRCC Receiving First-Line Pembrolizumab + Axitinib or Ipilimumab + Nivolumab